Navigation Links
Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis
Date:4/7/2011

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis. No pattern to this excess mortality was evident to researchers, but deaths were unrelated to the peginterferon treatment. Full findings are published in the April issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

Infection with hepatitis C virus (HCV) is the primary cause of chronic hepatitis in the U.S., and is a major cause of morbidity and mortality resulting from cirrhosis and hepatocellular carcinoma (HCC). According to the Centers for Disease Control and Prevention (CDC), 3.2 million American are infected with chronic HCV which accounts for up to 10,000 deaths annually in the U.S. The standard treatment for chronic HCV is a combination of pegylated interferon and ribavirina combination therapy which achieves sustained virological response rates of 40%-80% as reported by the CDC. Though antiviral therapy may decrease the rate of progression and death from chronic HCV, there is currently no beneficial therapy available for patients who fail to respond to standard treatment.

The initial HALT-C Triala randomized, controlled study of 1,050 chronic HCV patients with advanced fibrosis (n=622) or cirrhosis (n=428) who failed to achieve a sustained response from prior antiviral therapyevaluated the effects of low-dose maintenance therapy with peginterferon, compared to no therapy, in slowing disease progression and preventing end-stage liver disease, HCC, and death. The results from the randomized phase showed that long-term peginterferon treatment failed to produce a positive effect on clinical outcomes or death. Furthermore, the authors noted that excess mortality occurred in the treatment group among patients with advanced fibrosis without cirrhosis.

"We followed the trial participants for an additional three years to investigate whether the increased mortality persisted and to explore causes of death," said lead study author Adrian Di Bisceglie, MD, FACP, Chairman of the Department of Internal Medicine at Saint Louis University School of Medicine in Missouri. For the current analysis, a committee of investigators reviewed deaths occurring during and after the HALT-C Trial to determine the cause of death. The committee categorized each death as liver- or non-liver related, and whether or not the death was associated with complications of peginterferon.

Analysis showed that 18% of the trial participants died (122) or underwent liver transplantation (74) over a median of 5.7 years. Two thirds of the deaths (62%) were attributed to end-stage liver disease or HCC and the remaining deaths (38%) were attributed to non-liver-related causes. The cumulative seven-year mortality rate was 20% for patients in the treatment group compared to 15% in the non-treatment control. Researchers observed differences in mortality rates (by seven years) between the treatment and non-treatment groups which were statistically significant for patients with fibrosis (14% and 7%, respectively) compared to those with cirrhosis (28% and 26%, respectively).

Researchers noted that the increase in mortality for patients treated with peginterferon did not emerge until three years into treatment and continued for several years after treatment ceased. The excess mortality in the treatment group was mainly linked to non-liver-related causes. "No specific cause of death accounted for the excess mortality, but deaths were unrelated to direct effects of peginterferon treatment," concluded Dr. Di Bisceglie. Researchers could not identify an excess frequency of any single condition or disease category for cause of non-liver related deaths. Only one death was determined to be a probable result of complications from peginterferon therapy. "Our findings suggest that the long-term use of peginterferon should be evaluated cautiously and that attention to unrelated complications is warranted."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Emergency department CT exams of children have increased substantially
2. Children of women who smoked during pregnancy at increased risk of becoming smokers
3. Traffic accidents linked to increased risk of chronic widespread pain
4. Gardening linked to increased vegetable consumption in older adults
5. Heavy drinking associated with increased risk of death from pancreatic cancer
6. Adults With HIV at Increased Risk of Bone Fractures, Study Finds
7. Acquisition of robotic technology leads to increased rates of prostate cancer surgery
8. Non-steroidal anti-inflammatory drugs linked to increased risk of erectile dysfunction
9. Multiple childbirth linked to increased risk of rare, aggressive triple-negative breast cancer
10. High Triglyceride Levels Linked to Increased Stroke Risk: Study
11. Cell-phone use not related to increased brain cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... its newly redesigned website, federallabs.org . The site houses a wealth of ... available federal technologies through the process called technology transfer (T2). As a network ...
(Date:2/8/2016)... ... ... famous for gift giving with flowers, chocolates and other tokens of affection meant to remind ... than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts - no matter ... they’ve led and the people they’ve touched. , That’s why Give To ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... and clothing, announced expansion into Canada to provide its range of unique and ... sales office in Quebec City that will provide bilingual customer service and marketing ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Delta Dental of ... help combat pancreatic cancer. , Gary D. Radine, who recently retired as president and ... American Cancer Society’s 2015 CEO of the Year , helped lead the effort ...
(Date:2/8/2016)... ... 08, 2016 , ... FileHold's document management software has been ... cloud hosted environment for FileHold software that is pay per user subscription-based and ... using the FileHold web services API. DocuSyst also advises clients on fully functioning ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... that the U.S. Food and Drug Administration (FDA) ... application for SB-318, a single treatment strategy intended ... I (MPS I). The SB-318 IND application is ... Phase 1/2 clinical study (SB-318-1502) designed to assess ...
(Date:2/8/2016)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced ... Food and Drug Administration (FDA) on February 4, 2016, ... on the clinical studies being conducted under the Company,s ... hold impacts part of the clinical work currently being ... clinical trials. --> ...
(Date:2/5/2016)... Feb. 5, 2016 Amgen (NASDAQ: AMGN ) ... Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Feb. ... David W. Meline , executive vice president and chief ... audio of the presentation can be accessed from the Events ... replay of the webcast will also be available on Amgen,s ...
Breaking Medicine Technology: